Health Care·Health Care Equipment·$92.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.18 | N/A | +13.21% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.18 | N/A | +13.21% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They emphasized their commitment to enhancing product offerings.
Management highlighted strong performance in key product segments.
They noted ongoing investments in innovation to drive future growth.
Boston Scientific's earnings report shows a positive surprise in EPS, which likely contributed to the stock's 12.7% increase. The strong EPS performance indicates effective cost management and possibly better-than-expected sales in certain areas. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 22, 2013